Skip to main content
. 2024 Sep;30(9):1978–1980. doi: 10.3201/eid3009.240118

Table. Survey regarding 158 infectious diseases clinicians’ awareness of antifungal-resistant dermatophyte infections and access to laboratory testing, United States, 2023.

Survey query No. (%) respondents
Primary setting of clinical practice
University hospital 75 (47)
Community hospital 26 (16)
Non-university teaching hospital 19 (12)
Veterans Affairs hospital or Department of Defense 13 (8)
Outpatient setting only 8 (5)
Free-standing children’s hospital 5 (3)
City, county, or public hospital 4 (3)
Other 4 (3)
Question not answered
4 (3)
Type of clinical practice
Adult infectious diseases physician 126 (80)
Pediatric infectious diseases physician 19 (12)
Pharmacist 6 (4)
Nurse practitioner, physician assistant, or physician associate 2 (1)
Other 4 (3)
Question not answered
1 (1)
How did you hear about the issue of antifungal-resistant dermatophyte infections? (select all that apply)
I had not previously heard of this issue 55 (35)
Answers among those who had heard of this issue, n = 103
Emerging Infections Network emails 60 (58)
CDC webpage or Morbidity and Mortality Weekly Report 46 (45)
Scientific publication 28 (27)
News reports 18 (17)
From clinical colleagues 18 (17)
Clinician education website (e.g., Doximity and Medscape) 6 (6)
Point-of-care medical resource (e.g., UpToDate) 4 (4)
Social media 2 (2)
Other
6 (6)
In the past year, I have seen or consulted on a patient with a dermatophyte infection that was potentially resistant to treatment or concerning for resistance
Yes 27 (17)
No 119 (75)
Unknown
12 (8)
If I saw a patient with a potentially resistant dermatophyte infection, I would be able to obtain laboratory testing to determine the species
Yes 83 (53)
No 26 (16)
Unknown
49 (31)
I would be able to obtain testing to determine if a dermatophyte is resistant to antifungals
Yes 62 (39)
No 25 (16)
Unknown 71 (45)